Differences Between Old and Young Mesenchymal Stem Cells for Drug Metabolism
Conference Recording May 15, 2013
About the SpeakerProf. Andreas K. Nüssler is a German native. He studied Pharmacy and human biology in Germany and France. He received his PhD from University Paris VI, France in 1991. From 1991 to 1994 he worked as Research Assistant Prof. at Pittsburgh Medical School, USA. Between 1994 & 2003, he was group leader in the experimental surgery unit at the University of Ulm and the Charité in Berlin, Germany. Between 2003 & 2007 he worked as CSO and Program Manager at Fresenius and its subsidiaries. Between 2007 and 2011 he was head of R&D at the Technical University Munich. Since Sept. 2011 he fulltime joint the University Tübingen where he is head of a newly formed research unit to coordinate clinical and basic research in the department of traumatology. He has published over 250 peer-review papers, book chapters, reviews and proceedings. He is reviewer for int. journals and organizations and is involved in many national and int. research clusters. His major scientific interests are the use of human liver cell culture models, AdMSCs-derived cells in aging and tissue regeneration (in particularly liver regeneration) and their use in in-vitro metabolisms.
There is increasing evidence that mesenchymal stem cells can differentiate into hepatocyte-like cells. However many open questions remain in order to use these cells routinously in drug development. The present paper will present advantages and disadvantages using MSCs in drug development.